Skip to Main Content

Author Details

Timothy L Ratliff
Purdue University
1978
248
62
Jake Y. Chen (CM4AI)
PMIDPaper TitleJournal TitlePublished Year
37001528Challenges and opportunities for modeling aging and cancer.Cancer Cell2023
37001528Challenges and opportunities for modeling aging and cancer.Cancer Cell2023
34728570Targeting DNMTs to Overcome Enzalutamide Resistance in Prostate Cancer.Mol Cancer Ther2022
35440548TNF is a potential therapeutic target to suppress prostatic inflammation and hyperplasia in autoimmune disease.Nat Commun2022
36082359Targeted elastin-like polypeptide fusion protein for near-infrared imaging of human and canine urothelial carcinoma.Oncotarget2022
35609195A single local delivery of paclitaxel and nucleic acids via an immunoactive polymer eliminates tumors and induces antitumor immunity.Proc Natl Acad Sci U S A2022
36969745Tumor Cell-Autonomous SHP2 Contributes to Immune Suppression in Metastatic Breast Cancer.Cancer Res Commun2022
36480485Monocytic Myeloid-Derived Suppressor Cells from Tumor Tissue Are a Differentiated Cell with Limited Fate Plasticity.Immunohorizons2022
34728570Targeting DNMTs to Overcome Enzalutamide Resistance in Prostate Cancer.Mol Cancer Ther2022
35027481Targeting Protein Arginine Methyltransferase 5 Suppresses Radiation-induced Neuroendocrine Differentiation and Sensitizes Prostate Cancer Cells to Radiation.Mol Cancer Ther2022
35440548TNF is a potential therapeutic target to suppress prostatic inflammation and hyperplasia in autoimmune disease.Nat Commun2022
35609195A single local delivery of paclitaxel and nucleic acids via an immunoactive polymer eliminates tumors and induces antitumor immunity.Proc Natl Acad Sci U S A2022
36969745Tumor Cell-Autonomous SHP2 Contributes to Immune Suppression in Metastatic Breast Cancer.Cancer Res Commun2022
36480485Monocytic Myeloid-Derived Suppressor Cells from Tumor Tissue Are a Differentiated Cell with Limited Fate Plasticity.Immunohorizons2022
36082359Targeted elastin-like polypeptide fusion protein for near-infrared imaging of human and canine urothelial carcinoma.Oncotarget2022
35027481Targeting Protein Arginine Methyltransferase 5 Suppresses Radiation-induced Neuroendocrine Differentiation and Sensitizes Prostate Cancer Cells to Radiation.Mol Cancer Ther2022
33064371Thrombin-PAR1 signaling in pancreatic cancer promotes an immunosuppressive microenvironment.J Thromb Haemost2021
33203700Folate Receptor Beta Designates Immunosuppressive Tumor-Associated Myeloid Cells That Can Be Reprogrammed with Folate-Targeted Drugs.Cancer Res2021
33064371Thrombin-PAR1 signaling in pancreatic cancer promotes an immunosuppressive microenvironment.J Thromb Haemost2021
33203700Folate Receptor Beta Designates Immunosuppressive Tumor-Associated Myeloid Cells That Can Be Reprogrammed with Folate-Targeted Drugs.Cancer Res2021
31584195A novel, safe, fast and efficient treatment for Her2-positive and negative bladder cancer utilizing an EGF-anthrax toxin chimera.Int J Cancer2020
31584195A novel, safe, fast and efficient treatment for Her2-positive and negative bladder cancer utilizing an EGF-anthrax toxin chimera.Int J Cancer2020
32307923Functionalized NIR-II Semiconducting Polymer Nanoparticles for Single-cell to Whole-Organ Imaging of PSMA-Positive Prostate Cancer.Small2020
317831501α, 25 Dihydroxyvitamin D (1,25(OH)<sub>2</sub>D) inhibits the T cell suppressive function of myeloid derived suppressor cells (MDSC).J Steroid Biochem Mol Biol2020
32039002Naturally-Occurring Invasive Urothelial Carcinoma in Dogs, a Unique Model to Drive Advances in Managing Muscle Invasive Bladder Cancer in Humans.Front Oncol2020
33093218Pharmacologic Inhibition of FGFR Modulates the Metastatic Immune Microenvironment and Promotes Response to Immune Checkpoint Blockade.Cancer Immunol Res2020
32999000Protein Arginine Methyltransferase 5 Promotes pICln-Dependent Androgen Receptor Transcription in Castration-Resistant Prostate Cancer.Cancer Res2020
317831501α, 25 Dihydroxyvitamin D (1,25(OH)<sub>2</sub>D) inhibits the T cell suppressive function of myeloid derived suppressor cells (MDSC).J Steroid Biochem Mol Biol2020
32039002Naturally-Occurring Invasive Urothelial Carcinoma in Dogs, a Unique Model to Drive Advances in Managing Muscle Invasive Bladder Cancer in Humans.Front Oncol2020
33093218Pharmacologic Inhibition of FGFR Modulates the Metastatic Immune Microenvironment and Promotes Response to Immune Checkpoint Blockade.Cancer Immunol Res2020
32999000Protein Arginine Methyltransferase 5 Promotes pICln-Dependent Androgen Receptor Transcription in Castration-Resistant Prostate Cancer.Cancer Res2020
32307923Functionalized NIR-II Semiconducting Polymer Nanoparticles for Single-cell to Whole-Organ Imaging of PSMA-Positive Prostate Cancer.Small2020
30716360Identification of LIMK2 as a therapeutic target in castration resistant prostate cancer.Cancer Lett2019
31657935Sustained Delivery of Carfilzomib by Tannic Acid-Based Nanocapsules Helps Develop Antitumor Immunity.Nano Lett2019
30824526Cholesterol Sulfotransferase SULT2B1b Modulates Sensitivity to Death Receptor Ligand TNFα in Castration-Resistant Prostate Cancer.Mol Cancer Res2019
31212370Distinct expression patterns of SULT2B1b in human prostate epithelium.Prostate2019
30940724NOTCH signaling is activated in and contributes to resistance in enzalutamide-resistant prostate cancer cells.J Biol Chem2019
30716360Identification of LIMK2 as a therapeutic target in castration resistant prostate cancer.Cancer Lett2019
31657935Sustained Delivery of Carfilzomib by Tannic Acid-Based Nanocapsules Helps Develop Antitumor Immunity.Nano Lett2019
31212370Distinct expression patterns of SULT2B1b in human prostate epithelium.Prostate2019
30940724NOTCH signaling is activated in and contributes to resistance in enzalutamide-resistant prostate cancer cells.J Biol Chem2019
30824526Cholesterol Sulfotransferase SULT2B1b Modulates Sensitivity to Death Receptor Ligand TNFα in Castration-Resistant Prostate Cancer.Mol Cancer Res2019
29732386Naturally-Occurring Canine Invasive Urothelial Carcinoma: A Model for Emerging Therapies.Bladder Cancer2018
30190370Dietary Protein Restriction Reprograms Tumor-Associated Macrophages and Enhances Immunotherapy.Clin Cancer Res2018
30040650"Super Gene Set" Causal Relationship Discovery from Functional Genomics Data.IEEE/ACM Trans Comput Biol Bioinform2018
29732386Naturally-Occurring Canine Invasive Urothelial Carcinoma: A Model for Emerging Therapies.Bladder Cancer2018
29545473Cholesterol Esterification Inhibition Suppresses Prostate Cancer Metastasis by Impairing the Wnt/β-catenin Pathway.Mol Cancer Res2018
30190370Dietary Protein Restriction Reprograms Tumor-Associated Macrophages and Enhances Immunotherapy.Clin Cancer Res2018
30040650"Super Gene Set" Causal Relationship Discovery from Functional Genomics Data.IEEE/ACM Trans Comput Biol Bioinform2018
29545473Cholesterol Esterification Inhibition Suppresses Prostate Cancer Metastasis by Impairing the Wnt/β-catenin Pathway.Mol Cancer Res2018
  • 1 - 50 of 496

Recommended Authors

Stanford University
Career Start Year 2000
Number of shared co-authors 0
Center for Cancer Research
Career Start Year 1999
Number of shared co-authors 0
Frederick National Laboratory for Cancer Research
Career Start Year 1996
Number of shared co-authors 1
University of Texas Southwestern Medical Center at Dallas
Career Start Year 1994
Number of shared co-authors 3
University of California Riverside
Career Start Year 1992
Number of shared co-authors 0
Washington State University Elson S. Floyd College of Medicine
Career Start Year 1992
Number of shared co-authors 2
University of Colorado School of Medicine
Career Start Year 1991
Number of shared co-authors 2
Center for Cancer Research, National Cancer Institute, National Institutes of Health
Career Start Year 1991
Number of shared co-authors 0
Robert H Lurie Comprehensive Cancer Center of Northwestern University
Career Start Year 1991
Number of shared co-authors 0
The University of Texas MD Anderson Cancer Center
Career Start Year 1990
Number of shared co-authors 2
Centre de recherche sur le cancer de l'Universite Laval
Career Start Year 1990
Number of shared co-authors 0
Michigan Center for Translational Pathology, University of Michigan ann arbor
Career Start Year 1988
Number of shared co-authors 2
Institute for Research in Immunology and Cancer (IRIC), University of Montreal
Career Start Year 1986
Number of shared co-authors 0
Eastern Virginia Medical School
Career Start Year 1985
Number of shared co-authors 3
David Geffen School of Medicine at university of california los angeles
Career Start Year 1984
Number of shared co-authors 0
Center for Cancer Research, National Cancer Institute
Career Start Year 1984
Number of shared co-authors 0
Sandra and Edward Meyer Cancer Center
Career Start Year 1983
Number of shared co-authors 0
Queen's University
Career Start Year 1982
Number of shared co-authors 2
The Brady Urological Institute, Johns Hopkins University School of Medicine
Career Start Year 1981
Number of shared co-authors 4
University of Washington School of Medicine
Career Start Year 1980
Number of shared co-authors 4
Universite de Paris-Cite
Career Start Year 1979
Number of shared co-authors 0
The Institute of Cancer Research
Career Start Year 1978
Number of shared co-authors 0
The University of Texas MD Anderson Cancer Center
Career Start Year 1978
Number of shared co-authors 1
College of Agriculture and Life Sciences, Cornell University
Career Start Year 1977
Number of shared co-authors 1
The Institute of Cancer Research
Career Start Year 1977
Number of shared co-authors 0
CHU de Quebec-Universite Laval
Career Start Year 1975
Number of shared co-authors 4
University of Alabama at Birmingham
Career Start Year 1974
Number of shared co-authors 1
University of Washington
Career Start Year 1974
Number of shared co-authors 2
Uppsala University
Career Start Year 1970
Number of shared co-authors 0
National Centre for Asbestos Related Diseases, University of Western Australia
Career Start Year 1967
Number of shared co-authors 0

Collaborators

Queen's University
Co-authored papers 8
University of Pittsburgh School of Medicine
Co-authored papers 5
Co-authored papers 4
Yale University School of Medicine
Co-authored papers 4
Duke University School of Medicine
Co-authored papers 3
Co-authored papers 3
University of Alabama at Birmingham, USA Informatics Institute
Co-authored papers 2
Co-authored papers 2
University of Alabama at Birmingham
Co-authored papers 2
Co-authored papers 2
Co-authored papers 2
University of Alabama at Birmingham
Co-authored papers 2
Center for Cancer Research, and Institute for Drug Discovery, Purdue University
Co-authored papers 1
Memorial Sloan Kettering Cancer Center
Co-authored papers 1
Dana-Farber Cancer Institute, Brigham and Women's Hospital, Harvard Medical School
Co-authored papers 1
University of Texas MD Anderson Cancer Center
Co-authored papers 1
Co-authored papers 1
Dana-Farber Cancer Institute
Co-authored papers 1
Earle A. Chiles Research Institute, Providence Cancer Institute
Co-authored papers 1
University of British Columbia
Co-authored papers 1
Co-authored papers 1
University of Vermont
Co-authored papers 1
Mayo Clinic
Co-authored papers 1
University of Vermont
Co-authored papers 1
NorthShore University HealthSystem, Research Institute, 1001 University Place
Co-authored papers 1
Icahn School of Medicine at Mount Sinai
Co-authored papers 1
Seoul National University Bundang Hospital and College of Medicine
Co-authored papers 1
Harbin Medical University
Co-authored papers 1
Division of Clinical Chemistry, Johns Hopkins University
Co-authored papers 1
Co-authored papers 1